C&R Research Inc

C&R Research Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.15, significantly below the industry median of 0.45, indicating a low leverage profile. The company's liquidity position is robust, with cash and equivalents of KRW 8.85 billion and a current ratio of 1.19, suggesting it can meet short-term obligations without external financing. However, negative operating cash flow of KRW -3.07 billion highlights operational inefficiencies or strategic investments in growth. Profitability metrics show a return on equity (ROE) of 5.23% and return on assets (ROA) of 3.05%, both below the industry median of 7.8% and 4.5%, respectively. The company's net income of KRW 2.59 billion on revenue of KRW 64.98 billion reflects a net margin of 3.98%, which is in line with the sector average of 4.1%. However, operating income of KRW 1.38 billion implies an operating margin of 2.13%, below the median of 3.2% for Biotechnology & Medical Research firms. The company's revenue is concentrated in its core clinical trial agency and drug development services, with no disclosed geographic diversification beyond South Korea. This lack of geographic segmentation increases exposure to local regulatory and economic conditions, which could impact revenue stability. Looking ahead, the company is projected to grow revenue by 12.3% in the current fiscal year and 8.7% in the next, driven by expansion in global clinical trial development services. Free cash flow of KRW 1.29 billion supports reinvestment in operations, though capital expenditures of KRW -284.7 million suggest a focus on cost control. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong equity position reduce financial distress risk, though the negative operating cash flow could signal near-term operational challenges. No dilution sources were identified in recent filings, and the probability of near-term dilution remains low. Recent filings and transcripts show no material events affecting the company's operations or financial position. The absence of significant regulatory or litigation risks supports the low-risk profile, though the company's reliance on a single geographic market remains a concentration risk.